Search clinical trials for: IMATINIB MESYLATE

Total 1350 results

Fox Chase Cancer Center
Novartis

Terminated

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Metastatic Disease | GIST

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Leukemia, Myeloid, Chronic

Israel
Novartis

Terminated

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Glioblastoma

Brazil
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib in Chordoma

Chordoma

Switzerland, Italy
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Chronic Myelomonocytic Leukemia | Hypereosinophilic Syndrome | Systemic Mastocytosis | Dermatofibrosarcoma

Australia
Novartis Pharmaceuticals

Completed

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Gastrointestinal Stromal Tumors

Japan
Novartis Pharmaceuticals

Completed

Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Bristol-Myers Squibb

Completed

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (DASISION)

Myeloid Leukemia, Chronic

Germany, India, Japan, Korea, Republic of, Turkey, Chile, China, Spain, Australia, France, Poland, Mexico, Colombia, Belgium, Austria, Italy, Peru, Greece, Brazil, Czech Republic, Hungary, Russian Federation, Netherlands, Argentina, Den... and more
University of Utah
Schering-Plough

Terminated

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Gastrointestinal Stromal Tumors | Solid Tumors | Cancer Brain

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer (INV181)

Breast Cancer

Germany
Dana-Farber Cancer Institute
Novartis; Brigham and Women's Hospital

Completed

Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T Cell Non-Hodgkin Lymphoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Brigham and Women's Hospital

Completed

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

Myelofibrosis | Chronic Myelomonocytic Leukemia | Myeloid Metaplasia | Agnogenic Myeloid Metaplasia

United States
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States
Hikma Pharmaceuticals LLC

Completed

Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan (CCMLJ)

Chronic Myeloid Leukemia, Chronic Phase

Jordan
Novartis Pharmaceuticals

Completed

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer (INV342)

Prostate Cancer

Germany
Novartis Pharmaceuticals

Completed

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Life Threatening Diseases
Novartis Pharmaceuticals

Completed

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) (CONVERT)

Gastrointestinal Stromal Tumors

Brazil
University of Michigan Rogel Cancer Center

Terminated

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
Poitiers University Hospital

Completed

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia

France
Bristol-Myers Squibb

Completed

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Leukemia, Myeloid, Chronic-Phase (CML-CP)
Kerman University of Medical Sciences

Terminated

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Chronic Myelogenous Leukemia

Iran, Islamic Republic of
Sun Yat-sen University

Unknown

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study (GITIC)

Gastrointestinal Cancers

China
UNICANCER

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Desmoid Tumor

France
Hospital Virgen de la Salud

Completed

Imatinib in KIT-negative Systemic Mastocytosis

Systemic Mastocytosis

Spain
NYU Langone Health
Novartis

Terminated

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Prostatic Neoplasms | Prostate Cancer

United States
Assistance Publique - Hôpitaux de Paris
Group for Research in Adult Acute Lymphoblastic Leukemia

Completed

Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

Leukemia, Lymphocytic

France
University of Pittsburgh
Novartis

Completed

Effect of Antacids on Gleevec® in Healthy Volunteers

Healthy

United States
University of Pittsburgh
Novartis

Completed

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

Healthy

United States
Novartis Pharmaceuticals

Completed

A Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)

Gastrointestinal Stromal Tumor (GIST)

China, South Africa, United States, France, Italy, United Kingdom, Germany, Taiwan, Turkey, Canada, Egypt, Singapore, Argentina, Austria, Poland, Russian Federation, Spain, Sweden, Thailand, Korea, Republic of, Bulgaria, Denmark, Japan and more
Lee, Stephanie
National Cancer Institute (NCI)

Completed

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Systemic Scleroderma | Graft Versus Host Disease

United States
SCRI Development Innovations, LLC
Novartis; Aventis Pharmaceuticals

Completed

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center

Completed

Late Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
Novartis

Completed

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myeloid, Chronic

United States
Novartis Pharmaceuticals

Completed

Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Chronic Myeloid Leukemia (CML)

Korea, Republic of
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

Chronic Myeloid Leukemia

China
Indiana University

Completed

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Neurofibromatosis

United States
Novartis

Completed

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

Healthy
Novartis Pharmaceuticals

Completed

Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib

Healthy
Il-Yang Pharm. Co., Ltd.

Completed

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Philadelphia Chromosome

Korea, Republic of, Indonesia, Thailand, Philippines
Meng Li

Unknown

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia (SESPI)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Daniela Matei, MD
Sanofi; Novartis Pharmaceuticals; Walther Cancer Institute

Completed

Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

Ovarian Cancer

United States
Novartis Pharmaceuticals

Completed

Imatinib (QTI571) in Pulmonary Arterial Hypertension (IMPRES)

Pulmonary Arterial Hypertension

United States, Switzerland, Germany, Belgium, Spain, United Kingdom, Italy, Korea, Republic of, Netherlands, Canada, Sweden, Austria, Japan, France
Bristol-Myers Squibb

Withdrawn

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

United States
Bristol-Myers Squibb

Completed

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (START rollover)

Leukemia

Germany, Italy, Korea, Republic of, Sweden, Thailand, United States, Australia, France, Poland, Switzerland, Spain, Ireland, Peru, Brazil, South Africa, Canada, Argentina, Hungary, Finland, Israel, Norway, Russian Federation, United... and more
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

Therapy of Early Chronic Phase CML With Gleevec

Leukemia, Myeloid, Chronic-Phase

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Choroidal Neovascularization

United States

Search clinical trials for: IMATINIB MESYLATE

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations